Patents by Inventor Michael KOTHE

Michael KOTHE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS
    Publication number: 20240189322
    Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
    Type: Application
    Filed: November 21, 2023
    Publication date: June 13, 2024
    Inventors: John L. KANE, JR., Gloria MATTHEWS, Markus METZ, Michael KOTHE, Jinyu LIU, Andrew SCHOLTE
  • TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS
    Publication number: 20190183903
    Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
    Type: Application
    Filed: November 19, 2018
    Publication date: June 20, 2019
    Inventors: John L. KANE, JR., Gloria MATTHEWS, Markus METZ, Michael KOTHE, Jinyu LIU, Andrew SCHOLTE
  • TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS
    Publication number: 20170224704
    Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
    Type: Application
    Filed: February 17, 2017
    Publication date: August 10, 2017
    Inventors: John L. KANE, JR., Gloria MATTHEWS, Markus METZ, Michael KOTHE, Jinyu LIU, Andrew SCHOLTE
  • TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS
    Publication number: 20150274725
    Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
    Type: Application
    Filed: June 16, 2015
    Publication date: October 1, 2015
    Inventors: John L. KANE, JR., Gloria MATTHEWS, Markus METZ, Michael KOTHE, Jinyu LIU, Andrew SCHOLTE
  • TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS
    Publication number: 20150191466
    Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
    Type: Application
    Filed: February 23, 2015
    Publication date: July 9, 2015
    Inventors: John L. KANE, JR., Gloria MATTHEWS, Markus METZ, Michael KOTHE, Jinyu LIU, Andrew SCHOLTE
  • TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS
    Publication number: 20150158847
    Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
    Type: Application
    Filed: December 9, 2014
    Publication date: June 11, 2015
    Inventors: John L. KANE, JR., Gloria MATTHEWS, Markus METZ, Michael KOTHE, Jinyu LIU, Andrew SCHOLTE